Engineering immuno-therapies and vaccines
for cancers and infectious diseases
ElicioTherapeutics is advancing the Amphiphile technology across immunotherapy and vaccine platforms to defeat cancers and infectious diseases. By combining expertise in materials science, immunology, and vaccines, Elicio is engineering potent Amphiphile immunotherapies that precisely target and fully engage the lymph nodes, the site in our bodies where the immune response is orchestrated. Elicio is engineering lymph node targeted cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases. The Amphiphile platform emerged from laboratories of Darrell Irvine, Howard Hughes Investigator and Professor of Biomedical Engineering in the Koch Institute of Integrative Cancer Research at MIT.